It did (as it almost always does) outspend Merck but was dwarfed by Amazon. . . and ran neck in neck with Amgen this quarter. Again, odd that more than $3.25 million was spent, right into the teeth of the mid-terms -- when Congress-critters won't really do much of anything remotely risky . . . except campaign. The voters generally don't love PhRMA's "price protection" efforts, so House members of both parties tend to go into hiding on legislative jaw-boning -- at least in public -- until the November election results are in. Here's the run down, in any event:
. . .Drug Pricing [Generally]; Support of Biosimilars; Out-of-Pocket Costs; Rebate Reform; Vaccine Infrastructure/HR 3656 Excise Tax- S.3087; Antimicrobial Resistance/HR 3932/PASTEUR Act; COVID Relief Package/Appropriations; PDUFA. . . .
Medicare Part D support for access to treatments for obesity; Coverage Gap; Rebate Reform; Out-of-Pocket Costs; Government Negotiation in Medicare. . . .
Comprehensive Corporate Tax Reform; International Tax Reform; OECD Profit Allocation; U.S. Manufacturing Credits; Build Back Better Act; Minimum Tax. . . .
NAFTA/USMCA; Foreign Market Access issues (including IPR); International Supply Chain/Buy America -- harmonize international drug manufacturing standards; Global Access to Medicines. . . .
TRIPS Waiver; General IP Issues; Bayh-Dole March-In Rights. . . .
Now you know -- onward, to goblins and ghosties, Monday night!
नमस्ते
No comments:
Post a Comment